Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin twice-daily versus once-daily add-on to metformin in type 2 diabetes
2009-013549-27Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c after 12 weeks of treatment. Started Sep 2009; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-013549-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013549-27.